European Parliament greenlights Horizon Europe priorities
As a first result of the trilogue on the 100m+ Horizon Europe programme, MEPs backed the backbone of the EU’s future research and innovation programme.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
Entries by Thomas Gabrielczyk
Biotechpharma UAB expanding production
/in News/by Thomas GabrielczykLituanian CDMO Biotechpharma UAB has invested 50m in order to expand its production capacity to 5000 litres.
Kiadis Pharma NV to acquire CytoSen Therapeutics, Inc.
/in News/by Thomas GabrielczykKiadis Pharma NV has entered a definitive agreement to acquire US-based CytoSen Therapeutics, Inc. in order to create a leader in cell-based cancer immunotherapy.
Treating diabetes by mimicking gut bacteria effects
/in News/by Thomas GabrielczykResearchers at University of Glasgow report that modulation of a specific GPCR results in health benefits normally mediated by a healthy gut microbiome.
Immunic lists at Nasdaq
/in News/by Thomas GabrielczykChronic inflammatory disease company Immunic Therapeutics starts Nasdaq-trade following merger with Vital Therapies.
Preventing virus infections in newborns
/in News/by Thomas GabrielczykScientists from Belgium and the US have found a way to prevent the devasting consequences of herpes infections for newborn babies.
Evotec and Indivumed join forces in CRC
/in News/by Thomas GabrielczykEvotec SE and Indivumed GmbH have entered into a drug R&D collaboration aimed at developing first-in-class colorectal cancer treatments.
Theranexus colloborates with AI expert Dyliss
/in News/by Thomas GabrielczykLyon-based neurology specialist Theranexus SA has launched a new bioinformatics partnership with systems biology data analysts from Dyliss (Dynamics, Logics and Inference for biological Systems and Sequences).
uniQure Receives FDA Fast Track Designation for AMT-130
/in News/by Thomas GabrielczykFollowing the FDA granted AMT-130 fast track designation, uniQure NV announced it will start Phase I/II testing of the Huntingtons Disease gene therapy in Q2/2019.
Sanofi ends option phase of rare disease partnership with Alnylam
/in News/by Thomas GabrielczykSanofi and Alnylam have agreed to end the research and option phase of the companies’ RNAi therapeutics alliance in rare genetic diseases.